Balchem (BCPC) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
1 May, 2026Executive summary
Achieved record Q1 2026 consolidated sales of $270.7 million, up 8.1% year-over-year, with growth across all business segments and strong cash flows.
Net earnings rose 8.7% to $40.3 million, with adjusted EBITDA up 12.1% to $74.3 million and robust free cash flow of $33.8 million.
Strategic growth initiatives, branded ingredient expansion, and international market penetration supported momentum and a favorable outlook.
Demonstrated resilience and adaptability amid evolving global market and geopolitical conditions.
Advanced sustainability efforts, including the release of the 2025 Sustainability Report and surpassing 2030 GHG reduction goals.
Financial highlights
Quarterly consolidated revenue reached $270.7 million, up 8.1% year-over-year, with gross margin dollars at $101.1 million and margin percent rising to 37.3%.
Adjusted EBITDA was $74.3 million, up 12.1%, with an adjusted EBITDA margin of 27.4%.
Net income was $40.3 million, up 8.7%, with diluted EPS of $1.25 and adjusted EPS of $1.33.
Cash flows from operations were $40.1 million, with free cash flow of $33.8 million and cash on hand of $72.9 million.
Operating expenses increased due to higher compensation and professional services.
Outlook and guidance
Management expects continued quarterly year-over-year consolidated growth, supported by strategic initiatives, innovation, and market trends.
Confident in ability to deliver top and bottom line growth for the remainder of 2026, with a focus on expanding market reach and portfolio.
Effective tax rate for full year expected to be around 23%, with some quarterly fluctuations.
Management remains nimble and flexible to adapt to evolving market and geopolitical conditions.
No material impact expected from recent Supreme Court tariff ruling or new tariffs; monitoring ongoing developments.
Latest events from Balchem
- Virtual meeting to vote on directors, auditor, and executive pay set for June 18, 2026.BCPC
Proxy filing27 Apr 2026 - Strong 2025 results, board elections, auditor ratification, and performance-based executive pay.BCPC
Proxy filing27 Apr 2026 - Record sales, earnings, and cash flow growth, with increased dividends and strong global expansion.BCPC
Q4 202520 Feb 2026 - Record Q2 earnings and margin gains led by Human Nutrition & Health and Specialty Products.BCPC
Q2 20242 Feb 2026 - Q3 2024 net earnings rose 16.4% on 4.3% higher sales, led by Human Nutrition & Health.BCPC
Q3 202418 Jan 2026 - Record Q1 sales, double-digit profit growth, and margin expansion across all segments.BCPC
Q1 202524 Dec 2025 - Record sales, profit, and cash flow growth, with strong innovation and sustainability progress.BCPC
Q4 20249 Dec 2025 - Record financials, sustainability gains, and strong governance drive all Board-backed proposals.BCPC
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and executive pay up for vote at June 2025 meeting.BCPC
Proxy Filing1 Dec 2025